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The chylomicron remnant particle is thought to be
particularly atherogenic and we have previously
shown alterations in post-prandial lipoproteins
which could contribute to their atherogenicity.
Cholesterol metabolism is disturbed in diabetes, yet
the effect of diabetes on intestinal cholesterol synth-
esis and absorption has rarely been investigated. The
aim of this study was to examine cholesterol absorp-
tion and intestinal synthesis of cholesterol in the
streptozotocin diabetic rat. Twelve diabetic rats were
paired with 12 control rats. [14C]-Cholesterol emul-
sion was administered and the lymph duct was
canulated. Lymph was collected for 4 h. At sacrifice
blood was taken for plasma lipoprotein measure-
ments. Chylomicrons were prepared from the lymph
14 by ultracentrifugation and C]-cholesterol content
was determined by liquid scintillation counting.
Lymph apolipoprotein B48 was isolated by gradient
gel electrophoresis, and quantified by densitometric
scanning. Serum triglyceride and cholesterol were
greatly elevated in diabetic compared to control
animals (260 4- 90 and 9.8 4- 8.0 mg/ml vs. 1.0 4- 0.4
and 0.6 4- 0.3 mg/ml, p < 0.0001 respectively). Lymph
chylomicron apo B48 was similar in the two groups.
Cholesterol absorption was not significantly differ-
ent in diabetic compared to control rats but choles-
terol synthesis was significantly higher in the
diabetic animals (550 4- 352 vs. 322 4-113 g/h
p<0.03). There was a positive correlation between
apo B48 and cholesterol absorption (r 0.70, p < 0.01)
in the diabetic rats and control rats (r= 0.71, p < 0.01)
but no correlation between apo B48 and cholesterol
synthesis in either group. This study demonstrates
that cholesterol synthesis was increased in diabetes
whereas cholesterol absorption was unaffected sug-
gesting that intestinal cholesterol synthesis made an
important contribution to the hypercholesterolaemia
seen in the diabetic animals.
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Abbreviations: MTP, microsomal triglyceride transfer protein;
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zymeA cholesterol; acyltransferase HMGCoA, 3-hydroxy-3-
methylglutaryl coenzyme A
INTRODUCTION
The most important chronic complication of
diabetes is atherosclerosis. It is generally
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accepted that disturbance in cholesterol metabo-
lism is a major factor in the development of the
atherosclerotic plaque. The role of hyperglycae-
mia is uncertain with strong correlation’s
between hyperglycaemia and atherosclerosis
in many studies
[1,2] while the benefit of reduc-
tion in blood sugar has yet to be conclusively
demonstrated.
I3"4j Reducing serum cholesterol
has been shown to be beneficial in prevent-
ing myocardial infarction in non-diabetic sub-
jects
5-7j while both hypercholesterolaemic I81
and normocholesterolaemic [6] diabetic patients
showed even greater benefit from cholesterol
lowering, in secondary prevention studies, than
non-diabetic patients.
We and others have demonstrated alteration in
intestinal function in diabetes.I9-13 In particu-
lar we have shown in the animal model, an
increase in 3-hydroxy-3-methylglutaryl coen-
zyme A (HMGCoA) reductase and acylcoenzy-
meA cholesterol" acyltransferase (ACAT), [9,10]
the rate limiting enzymes for cholesterol synth-
esis, and more recently we have demonstrated a
5-fold increase in microsomal triglyceride trans-
fer protein (MTP) mRNA in the intestine of
diabetic animals.141 This enzyme is responsible
[15] for the assembly of the chylomicron. These
studies suggest an increase in synthesis of
cholesterol, together with an explanation for an
increase in the triglyceride load in the chylomi-
cron in diabetes.I16 Although we have shown
an increase in intestinally-derived apo B48-con-
taining particles both in the chylomicron and
the very low density lipoprotein (VLDL) fraction
in diabetes,I161 we are uncertain as to the role
of absorption and synthesis in relation to clear-
ance with regard to these particles. Definition of
the role of the intestine in cholesterol metabolism
may have relevance to the targeting of pharma-
cological agents in the treatment of the dyslipi-
daemia of diabetes. Having described the
increase inMTPmRNA in the intestine of diabetic
animals we now report our investigations into
cholesterol absorption as compared to intestinal
synthesis. In this study we examine cholesterol
absorption and synthesis in the streptozotocin
diabetic rat model, isolating intestinal function
by canulation of the lymphatic duct.
Animals
Twenty four male Sprague Dawley rats weigh-
ing between 350 and 500 g were fed a commer-
cial rat pelleted diet. The principals of laboratory
animal care (NIH publication number 85.23)
revised 1985 were followed. Animals were
housed under licence from the Department of
Health and experiments carried out according
to Irish law as administered by the Department
of Health. Twelve rats were made diabetic by
subcutaneous injection with streptozotocin (Sig-
ma, Poole UK) (60mg/Kg in 0.2mM sodium
citrate buffer, pH 4). Each diabetic rat was
paired with a control rat and the control rat
was injected with buffer alone. Urinary glucose
levels were monitored to confirm diabetic status.
Rats with a urine glucose of > 24mmol/1 were
considered to be diabetic and diabetes was
confirmed by blood glucose determination at
sacrifice. The weight and food intake of each
rat was monitored daily and the weight of the
intestine measured at sacrifice.
Lymph Duct Canulation
Five days after diabetes had been induced the
diabetic and control rat pairs were switched to a
diet of sunflower seeds. After two days on this
diet, control and insulin-deficient rats were
administered 1.5ml of a freshly prepared [14C]-
cholesterol emulsion by gavage. The emulsion
was prepared by mixing [4C]-cholesterol (4.4
mCi) (Amersham, UK) and 110mg non-radio-
active cholesterol dissolved in chloroform, with
90mg phosphatidyl choline (Sigma Poole UK).
The solvent was evaporated off under nitrogen
and the mixture sonicated with warm (55C)
saline for 20 minutes using a Branson Sonifier
250 probe at 50% duty cycle, output 5 with a flat
tip (Branson Ultrasonics, Danbury, CT, USA).CHOLESTEROL ABSORPTION AND SYNTHESIS IN DIABETES 205
One hour after gavage rats were anaesthetised
and a 2mm portex tube inserted in the thoracic
lymph duct through a transverse incision in the
abdominal wall. The tubing was allowed to exit
from the left hand side of the incision which
was then closed with 4.0 nylon suture. A small
section of the wound remained open to expose
the stomach. Rats were hydrated hourly by
gastric injection of 1.5ml normal saline and
lymph was collected for 4 hours. Rats remained
anaesthetised for the entire procedure. After 4
hours rats were exsanguinated by cardiac punc-
ture and the intestine removed and weighed.
METHODS
Lipoprotein Analysis
Triglyceride and cholesterol in rat serum was
determined by enzymatic colorimetric meth-
ods using kits from Boehringer Mannheim
(Mannheim Germany). Protein determination
was by the Bradford method using Coomassie
Protein Reagent (Pierce, Chester UK).
Preparation of Lymph Chylomicrons
Lymph was collected for 4 hours immediately
following canulation. Aprotinin (0.05 TIU) NaN3
(0.02%, w/v) EDTA (0.1%, w/v), PPACK II
(lmM), and PMSF (0.1mM) were added to
protect the lymph from oxidation and degrada-
tion. The volume of lymph collected was meas-
ured and aliquots reserved for counting and
analysis. The remainder was overlaid with
1.006 density solution and centrifuged at 10C in
a Sorval TFT 45.6 fixed angle rotor in a Sorval
Combi Plus centrifuge (Dupont, Wilmington,
DE, USA) for 30 minutes at 20,000 rev/min. The
opaque layer at the top of the tube containing
lymph chylomicrons was removed using a fine
glass pipette, the volume was measured and
chylomicrons were stored at 4C. ApoB48 was
determined within 1 week of lymph collection.
Quantification of apo B48
Lymph apo B48 (n=9) was measured using a
modification of the method previously described
for human plasma apo B48. [16"17] Lymph chylo-
microns were partially delipidated by mixing
62.5 pl of sample with 375 pl of diethyl ether.
Samples were centrifuged for 15 minutes in
microfuge, at 14,000 rev/min and the organic
phase discarded. The protein was dried and re-
dissolved in 24tl of denaturing buffer (0.1M
Tris HC1, pH 6.8, 4% (w/v) SDS, 2% (v/v) fl-
mercaptoethanol, 0.01% (w/v) bromophenol
blue, 20% (v/v) glycerol), heated for 5 minutes
at 96C, and loaded on a 4-15% polyacrylamide
gel. Electrophoresis was for 1 hour at 60mA
constant current in 0.019M Tris, 0.192M glycine.
LDL, isolated from human plasma by sequential
ultracentrifugation was used as an apo B100
protein standard. Apo B100 protein standards
(0.4 tg, 0.6 tg and 1.0 tg) were applied to each
gel. LDL protein concentration was calculated
from the mean value of ten determinations meas-
ured by modified Lowry procedure. Ilsl
Gels were stained for 1 hour with Coomassie
Blue R250 0.1% (w/v) in methanol: water: acetic
acid, (4:5 1 v/v) and destained with the same
solvent. The bands were quantified by densito-
metry using Vilber Lourmat equipment (Vilber
Lourmat Biotechnology, Marne le Vallee,
France). Video images of the gels were generated
and imported into BiolD v6.32 software (Vilber)
for analysis. Density values were assigned to
the apo B100 bands of the human LDL and a
standard curve constructed. Values were recal-
culated by linear regression and curves with a
correlation coefficient 0.95 accepted. The con-
centration of apo B48 was determined from
this standard. Previous researchers
[19] demon-
strated equal chromogenicity for apo B100 and
apo B48 bands and we have shown that apo
B100 staining is linear within the range 0.1-
2.0 tg of protein. Inter and intraassay variation
(n=6) for apo B48 determination were 3.9%
and 6% respectively.206 A. GLEESON et al.
Cholesterol Absorption and Synthesis
Intestinal cholesterol absorption and synthesis
were measured in the 12 pairs of diabetic and
control rats. Lymph was collected for 4 hours
and the volume measured.
To determine cholesterol absorption, [14C]-
cholesterol was measured in the emulsion and
lymph by liquid scintillation counting using
an LKB 1214 Rackbeta (Wallac). The specific
activities of [14C]-cholesterol was determined
in emulsion and lymph. The amount of lymph
[14C]-cholesterol (cpm/4h volume of lymph)
was related to the specific activity of the [14C]-
cholesterol administered by garage and divided
by 4 to give tg cholesterol absorbed/h.
Cholesterol synthesis was determined by
measuring total cholesterol in the 4 h collection
of lymph, dividing by 4 to give the amount/h
and subtracting the estimated amount of cho-
lesterol absorbed/h
Statistical Analysis
Results were expressed as mean+standard
deviation. Statistical analysis was performed
using the Student paired t-test and ANOVA
analysis of variance. Correlation coefficients
were determined by linear and multiple regres-
sion analysis using Statworks software on an
Apple Macintosh computer. Values of p <0.05
were considered to be statistically significant.
RESULTS
Rat characteristics on the day of test are shown
in Table I. Mean weight of control rat.s at the
beginning of the study was similar to the
diabetic rats but at the end of the diabetic rats
were significantly lighter than control animals
(p < 0.01) demonstrating the usual weight loss of
the diabetic animal model. Mean intestinal
weight of control animals at the end of the
study of was significantly lower than that of
the diabetic animals (p < 0.02). Blood glucose for
the control rats was 4.6+ 1.8 vs. 17.24-3.4
mmol/1 for the diabetic animals (p <0.0001).
Serum triglyceride in the control animals was
1.0 4- 0.4mg/ml and in the diabetic animals
260 4- 90mg/ml (p < 0.0001). Serum cholesterol
was 0.6 4- 0.3mg/ml in control rats vs. 9.8 4- 8.0
mg/ml in the diabetic rats (p <0.001). There was
no difference in serum protein or lymph
apo B48 between control and diabetic rats.
Cholesterol absorption was not significantly
different in the diabetic compared to control rats
(20.2 4- 19.4 vs. 27.7 tg/h 4- 27) (Fig. 1). Expressed
as cholesterol absorption/g intestine, the diabetic
animals having increased intestinal weight, it
was also not different (1.3 4- 1.3 tg/h/g intestine
for diabetic rats vs. 2.0 4- 1.9 tg/h/g intestine for
control rats). Cholesterol synthesis was signifi-
cantly higher in the diabetic rats (550 4- 352 vs.
3224- 113 g/h p<0.03) and was still signifi-
cantly greater when expressed per weight of rat
intestine (33.4 4- 25.3 vs. 22.4 4- 8.4 tg/h/g intes-
tine, p < 0.02). Lymph apo B48 was measured in 9
rat pairs and was not significantly different
between the two groups.
There was a positive correlation between
lymph apo B48 and cholesterol absorption in
the diabetic (r 0.70, p <0.01) and control rats
(r=0.71, p<0.01) (Fig. 2) but no correlation
between cholesterol synthesis and lymph apo
B48 in either group.
TABLE Rat characteristics on day of test
Diabetic Control p
Body weight
Intestinal weight (g)
Blood glucose (mmol/1)
Serum triglyceride (mmol/1)
Serum Cholesterol (mmol/1)
Lymph apo B48 (tg/h)(n 9)
368 4- 41
17.3 4- 2.7
17.2 4- 3.4
260 + 90
9.8 4- 8.0
9.1 4-4.0
425 4- 61 0.01
14.7 4- 2.7 0.02
4.6 + 1.8 0.0001
1.0 + 0.4 0.0001
0.6 4- 0.3 0.001
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FIGURE 1 Cholesterol synthesis and cholesterol absorption measured after an oral [14C]-cholesterol load in diabetic and
control rat pairs. Chylomicrons were isolated from lymph by ultracentrifugation. Chylomicron [14C]-cholesterol was related
to the specific activity of the administered emulsion and to the amount of non-radioactive cholesterol in the chylomicron
preparation. Mean + sd. p < 0.05 different from control.
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FIGURE 2 Relationship between lymph apo B48 and cholesterol absorption following an oral [14C]-cholesterol load in diabetic
and control rats. There was a significant positive correlation in both groups (r 0.71, p < 0.05 for control rats and r 0.70, p < 0.05
for diabetic rats).
DISCUSSION
We have previously shown an increase in
microsomal triglyceride transfer protein (MTP)
[14] in rat the diabetic intestine. In that study
lymph triglyceride and cholesterol were higher
in the diabetic rats while apo B48 was similar.
Diabetes in the rats was associated with weight208 A. GLEESON et al.
loss hypercholesterolaemia and hypertriglycer-
ideamia demonstrating insulinopaenia. Diabetes
results in intestinal hypertrophy in animals and
in this study we again found an increase in
intestinal weight in the diabetic animals. We and
others have previously demonstrated that the
intestinal hypertrophy in diabetes is associated
with an increase in HMGCoA reductase the rate
limiting enzyme for cholesterol synthesis. E9-111
We were particularly interested in this study
in whether the hypertrophied intestine found
in the diabetic rats would be associated with
increased cholesterol absorption as well as in-
creased cholesterol synthesis and the relation-
ship between intestinally-derived cholesterol
and apo B48. Our results demonstrate a sig-
nificant positive relationship between lymph
chylomicron apo B48 and cholesterol absorption
demonstrating that cholesterol absorption in
diabetes does not alter cholesterol content of
the chylomicron particle. In spite of the increase
in intestinal weight in diabetes, expression of
results per g intestine did not alter the results
significantly suggesting that the increase in
synthesis is not solely due to intestinal weight
in diabetes and this is supported by the finding
of no increase in cholesterol absorption and
indeed decrease in cholesterol absorption if de-
fined by intestinal weight. On the other hand
the increase in cholesterol synthesis in diabetes
showed no relationship to apo B48 and was
reflected in a cholesterol-enriched chylomicron
particle. Strandberg et al. E201 had demonstrated
low absorption and high synthesis of cholesterol
and bile acids in normal subjects with high
normal blood glucose with a suggestion that
there was a relationship between insulin sensi-
tivity and enhanced cholesterol synthesis. In-
creased cholesterol synthesis and decreased
absorption of cholesterol have been reported in
hypertriglyceridaemic subjects and more re-
cently Gylling et al. i211 demonstrated, in type 2
diabetes, increased synthesis and decreased
cholesterol absorption efficiency using non-
cholesterol sterols to reflect absorption and
synthesis. Our more direct measurements have
also shown increased intestinal cholesterol
synthesis but not absorption. This study allows
us, for the first time, to separate absorption and
synthesis from clearance. The method we have
used to calculate absorption does not include
cholesterol entering the intestinal mucosa from
circulating lipoproteins, which is thought to
be negligible in the postprandial state [22,23]
however it is worth noting that serum cholester-
ol was more than 15-fold higher in the diabetic
than control plasma. An interesting finding has
been the very strong association between cho-
lesterol absorption and apo B48 with no sugges-
tion that intestinal cholesterol synthesis affects
apo B48 production. Thus, a major defect of
cholesterol metabolism in the intestine in dia-
betes is the production of a cholesterol-enriched
particle.
Our recent finding of raised intestinal MTP
mRNA in diabetes under similar experimental
conditions I141 suggest that if MTP mRNA is
translated into MTP protein, MTP does not
stimulate apo B48 production. Van Greeven-
broek et al. [24] found, in Caco-2 cells (an
intestinally-derived cell line that secretes both
apo B100 and apo B48) that MTP inhibition
reduced apo B100 secretion but had no effect
on apo B48. Thus in the intestine MTP appears
to be important in regulating the triglyceride
content of the chylomicron particle without in-
creasing the number of particles. These studies
demonstrate that in diabetes the increase in
MTP mRNA is associated with a triglyceride-
enriched particle.
The effect of particle size on plasma clearance
of chylomicrons may be of great importance in
our quest to understand the atherogenicity of
the chylomicron particle. Martins et al. [25] have
examined the clearance from plasma of chylo-
micron emulsion particles. When equal numbers
of either small or large particles were injected
into rats the large particles were significantly
slower to clear than the small particles and
larger particles were found to be lipolysedCHOLESTEROL ABSORPTION AND SYNTHESIS IN DIABETES 209
significantly less than small ones. It is possible
that the delay in clearance of these large par-
ticles may impede the clearance of VLDL
particles since apo B48-containing particles are
preferentially taken up by the B/E receptor in
the liver.I26
In conclusion the present study has shown
that in diabetes cholesterol absorption was not
disturbed. Diabetes was associated with in-
creased intestinal cholesterol synthesis but the
increased cholesterol synthesis did not have
an effect on apo B48 production. This may be
the explanation for our previous finding of
increased lipid/apoB48 in the newly formed
chylomicron in diabetes.
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